CW July 2005
Volume 14Issue Number 7 July 2005 ISSN 10593802 PSA Response Not a Surrogate for Survival in Advanced Prostate CancerProstate-specific antigen (PSA) response cannot replace overall survival as the primary endpoint in phase III trials in metastatic hormone-refractory prostate cancer, according to a new study.
Go to Previous Page Go to Next Page Source and Additional Reading M. Roessner, 41st Annual Meeting of the American Society of Clinical Oncology. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW July 2005Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
